Mast cell leukaemia: evidence for bone marrow origin of the pathological clone

Dalton, Rachel; Li, Chan; Batten, E.; Eridani, S

doi:10.1111/j.1365-2141.1986.tb04133.x

Cited by 73 publications

(26 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The cell surface phenotype of MCs in MCL includes various myeloid determinants and is quite similar when compared to the cell surface membrane phenotype of MCs in other variants of SM [9,10,[24][25][26][27]. Notably, leukemic MCs in MCL usually express CD9, CD25, CD33, CD44 and CD117 (KIT) [9,10,[25][26][27].…”

Section: Cell Surface Phenotype Of Mcs In Chronic MCLmentioning

confidence: 98%

“…In addition, MCs in MCL may express CD123 and HLA-DR. The CD2 antigen (LFA-2) is also detectable on MCs in a subset of patients with MCL [9,27]. However, compared to patients with indolent SM, the number of ´CD2-positive´ cases among MCL patients is low, and if detected on the surface of MCs, the levels of CD2 are usually lower compared to that found on MCs in indolent SM [25][26][27].…”

Section: Cell Surface Phenotype Of Mcs In Chronic MCLmentioning

confidence: 98%

“…Notably, leukemic MCs in MCL usually express CD9, CD25, CD33, CD44 and CD117 (KIT) [9,10,[25][26][27]. In addition, MCs in MCL may express CD123 and HLA-DR.…”

Section: Cell Surface Phenotype Of Mcs In Chronic MCLmentioning

confidence: 99%

“…The prognosis of patients with MCL is poor which is mostly because MCs in these patients are largely resistant against conventional drugs and targeted drugs, including tyrosine kinase inhibitors (TKI) directed against KIT D816V such as PKC412 (midostaurin) [4][5][6][7][8][9][10][43][44][45].…”

Section: Therapeutic Optionsmentioning

confidence: 99%

“…The bone marrow (BM) is always affected, resulting in peripheral cytopenia [5,6,[9][10][11]. The BM smear in these patients contains at least 20% atypical and mostly immature MCs [1][2][3][4].…”

mentioning

confidence: 99%

See 4 more Smart Citations

Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features

Valent¹,

Sotlar²,

Sperr³

et al. 2015

Leukemia Research

View full text Add to dashboard Cite

SummaryMast cell leukemia (MCL) is a rare form of systemic mastocytosis characterized by leukemic expansion of mostly immature mast cells, organ damage, drug-resistance, and a poor prognosis. Even when treated with chemotherapy, most patients have a life-expectancy of less than one year. However, there are rare patients with MCL in whom the condition is less aggressive and does not cause organ damage within a short time. In these patients, mast cells exhibit a more mature morphology when compared to acute MCL. A recently proposed classification suggests that these cases are referred to as chronic MCL. In the present article, we discuss clinical, histopathological and morphological aspects of acute and chronic MCL.

show abstract

Section: Cell Surface Phenotype Of Mcs In Chronic MCLmentioning

confidence: 98%

Section: Cell Surface Phenotype Of Mcs In Chronic MCLmentioning

confidence: 98%

“…Notably, leukemic MCs in MCL usually express CD9, CD25, CD33, CD44 and CD117 (KIT) [9,10,[25][26][27]. In addition, MCs in MCL may express CD123 and HLA-DR.…”

Section: Cell Surface Phenotype Of Mcs In Chronic MCLmentioning

confidence: 99%

Section: Therapeutic Optionsmentioning

confidence: 99%

mentioning

confidence: 99%

See 3 more Smart Citations

Chronic mast cell leukemia: A novel leukemia-variant with distinct morphological and clinical features

Valent¹,

Sotlar²,

Sperr³

et al. 2015

Leukemia Research

View full text Add to dashboard Cite

show abstract

Acute Myeloid Leukemia in Adults: Mast Cell Leukemia and Other Mast Cell Neoplasms

Stone

Schiffer

2017

Holland‐Frei Cancer Medicine

View full text Add to dashboard Cite

Overview Acute myeloid leukemia (AML) is the most common variant of acute leukemia occurring in adults, comprising approximately 80% of acute leukemia cases diagnosed in individuals of age >20 years. Remarkable advances in transfusion medicine, treatment of infections, development of potent antiemetics, improved chemotherapeutic approaches, and increased use of safer allogeneic transplantation have led to an improved outcome at least in younger patients. Moreover, a more sophisticated understanding of pathophysiology, particularly in the area of genomics, may soon lead to less toxic, patient‐specific, and more effective therapies. At present, approximately 80% of younger (age <60 years) adults and 30%–50% of all older patients achieve complete remission (CR) defined as a morphologically normal bone marrow with reasonable neutrophil and platelet counts and no evidence of extramedullary disease. Varying with patient age and other biologic factors, 10–70% of these complete responders can be expected to achieve long‐term survival with the likelihood that most of these individuals are cured of their disease. However, AML is largely an intrinsically chemoresistant disease, the outcome in older adults has changed little, and the chemotherapeutic approach has remained stagnant.

show abstract